Dr. Robin K. Dore, MD

Dr. Dore practices at Providence St. Joseph Hospital Orange in Orange, California, part of Providence Health & Services.

Dr. Dore's NPI, 1619972510, was assigned on June 16, 2005. Dr. Dore graduated from UC Irvine School of Medicine in 1974. Dr. Dore's California license number on file is G33113.

Dr. Dore's primary practice is Providence St. Joseph Hospital Orange, at 1100 West Stewart Dr, Orange, CA 92868 in Orange County. The practice phone is (714) 633-9111.

Dr. Dore's primary practice is Providence St. Joseph Hospital Orange in Orange, California, part of Providence Health & Services. Dr. Dore is also affiliated with UCI Health - Orange. The medical group on file is Robin K. Dore MD, Inc. Dmand AI also links Dr. Dore to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dore practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Dore's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Dore is board certified in internal medicine by the American Board of Internal Medicine. Dr. Dore has a license on file in California.

Dmand AI lists arteritis, arthritis, fibromyalgia and chronic pain, gout, joint arthropathy, joint pain, lupus and muscle pain, fibromyalgia, and limb pain among the conditions Dr. Dore treats.

CMS data shows 7,248 Medicare services from Dr. Dore across 15 procedure codes in 2024, for 1,398 Medicare patients. Medicare paid $379,377 for them. Every service was in an office.

CMS counts 1,398 Medicare patients who saw Dr. Dore in 2024. The largest group is 75 to 84, with 677 patients. 75% of them have arthritis, and 75% have high cholesterol. 2% are also on Medicaid. Their average risk score is 1.29, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Dore's median patient age at 77, with 86% women.

In 2024, Dr. Dore wrote 7,144 Medicare Part D claims for 988 patients. 84% of them were for generic drugs. CMS names the drug for 6,719 of them, across 97 drugs with 11 or more claims each, at $3,699,760 in total drug cost. In 2023, CMS named 7,036 claims across 96 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 37 out of 100 for Dr. Dore for performance year 2024, reported individually. Dr. Dore accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dore as offering telehealth.

Dmand AI links 32 papers to Dr. Dore, published from 2005 to 2022. 2018 was the busiest year, with 2. The most frequent topics are Bone Density, Double-Blind Method and Arthritis, Rheumatoid. Dr. Dore has published most often in Osteoporos Int. Dr. Dore's most frequent co-authors are Nancy E. Lane, MD, John Paul Bilezikian, MD and Bruce Howard Mitlak, MD.

Dmand AI links Dr. Dore to 6 clinical trials. Conditions studied include Lupus Erythematosus, Systemic, Arthritis, Psoriatic and Connective Tissue Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Dore that name 3 trials.

CMS Open Payments shows 4,408 general payments to Dr. Dore from 45 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. Amgen Inc. paid the most, $498,824. It also lists 17 research payments totaling $117,985 from 2016 to 2022, naming 3 clinical trials.

Dmand AI lists 12 awards for Dr. Dore, most recently CMS Stage 1 EHR in 2013.

Dr. Dore graduated from UC Irvine School of Medicine in 1974. Dr. Dore is a member of ACR.

Dr. Dore is in network with 2 carriers, including Blue Cross Blue Shield of Michigan and CMS Medicare. HMO plans come from the most carriers, 1. Check the plan with the practice before a visit.